China’s biotech rise is fueled by its 'first to file' patent system. Companies feed newly published patents into computers to design trivially different but functionally identical molecules, effectively creating a 'shadow generic industry' that undermines IP.

The Driscoll's blueberry saga illustrates the core paradox of US-China business relations. China's 1.4 billion consumers represent a market too large to ignore, yet the requirement to share trade secrets with local partners creates an unavoidable risk of losing control over core intellectual property.

Big Pharma's strategy differs by region: they are willing to acquire innovative US biotechs outright but prefer to only license assets from Chinese companies. This is because Chinese assets can be secured at significantly lower valuations without the complexities of a full M&A transaction, creating an exit dilemma for VCs in China.

Holding a patent provides no inherent protection. Its value is only realized through active, and expensive, legal defense against infringers. Therefore, a startup's focus should be on building a profitable business first to generate the capital needed to enforce its IP.

With Chinese biotechs developing therapies at unprecedented speed, a Western startup's primary defense is carefully managing its intellectual property. This requires being highly strategic about when to file patents, what to publish, and what to share publicly, as any information can be rapidly replicated by fast-moving global competitors.

The AI lobby's argument to ignore IP rights to outpace China is shortsighted. The US's global strength is built on robust IP protection. Eroding this standard domestically jeopardizes the ability to protect American innovations, like OpenAI's own models, abroad. Respecting IP is the long-term strategic play.

The old narrative of China's IP theft is outdated. Today, China's competitive advantage in sectors like biotech comes from its massive scale, significant resources, and collective lack of profit sensitivity. This combination allows it to dominate industries and destroy profitability for other global players, as previously seen in solar and EVs.

Driscoll's built its empire not by farming, but by breeding and patenting berry varieties. They license this valuable IP to growers worldwide, who then use Driscoll's branded packaging. This asset-light model focuses on high-margin research and branding, turning a commodity into a premium product and the farmer's market into a patent office.

When fruit grower Driscoll's expanded to China, it faced a unique form of intellectual property theft. Competitors didn't just copy methods; they physically stole patented blueberry plants, propagated them, and used state-backed financing to scale. This quickly turned China into the world's top producer, crashing prices and profits.